Association of Higher Circulating Insulin Antibody with Increased Mean Amplitude Glycemic Excursion in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional, Retrospective Case-Control Study
Table 1
Baseline characteristics of patients.
C ()
L (IA 5-15.53)
H ()
value/chi-square
value
Age (year)
0.228
0.797
Gender (M/F)
25/22
22/28
23/27
0.900d
0.638
Duration (month)
132 (120, 240)
174 (120, 240)
120 (72, 195)
5.134c
0.077
BMI (kg/m2)
0.118
0.888
IA (%)
2.97 (1.76, 4.15)
8.80 (6.48, 11.76)
31.72 (21.80, 43.72)
Ln(IA) (%)
a
ab
376.120
<0.001
HbA1c (%)
0.095
0.910
Sqrt (C-p 0) (ng/ml)
0.532
0.588
Sqrt (C-p 120) (ng/ml)
0.181
0.835
C-p 0 (-/+)
23/24
17/33
18/32
2.641
0.267
C-p 120 (-/+)
8/39
7/43
6/44
0.504
0.777
Insulin dose 1 (U/kg)
0.30 (0.24, 0.37)
0.30 (0.23, 0.40)
0.28 (0.20, 0.36)
2.619
0.270
Insulin dose 2 (U/kg)
0.20 (0.13, 0.28)
0.22 (0.18, 0.33)
0.19 (0.16, 0.26)
3.864
0.145
Daily insulin dose (U/kg)
0.51 (0.40, 0.60)
0.53 (0.42, 0.73)
0.49 (0.35, 0.59)
2.850
0.241
Insulin/insulin analogue
14/33
12/38
13/37
0.427d
0.808
Oral drugs
Met (-/+)
41/6
45/5
40/10
2.172d
0.338
Aca (-/+)
38/9
40/10
42/8
0.295d
0.863
Met+Aca (-/+)
43/4
48/2
44/6
2.218d
0.337
BMI: body mass index; IA: insulin antibody; Ln: base logarithm; HbA1c: glycosylated hemoglobin A1c; Sqrt: square root; C-p: C-peptide; C-p 0 (-): C-p ; C-p 0 (+): C-p ; C-p 120 (-): C-p ; C-p 120 (+): C-p ; insulin dose 1: insulin dose before breakfast; insulin dose 2: insulin dose before dinner; Met: metformin; Aca: acarbose. aCompared with the C group ();bcompared with the L group ();cnonparametric test; dChi-square test. Data were presented as or median (25th, 75th percentile).
